Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
respiratory syncytial virus fusion protein virus-like particle
- Development stage
- Unknown
- Lead developer
- VBI Vaccines
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Respiratory syncytial virus fusion protein virus-like particle (RSV F-VLP) is an experimental vaccine candidate developed using an enveloped virus-like particle (eVLP) platform. The vaccine consists of virus-like particles that display the RSV fusion (F) protein on their surface, mimicking the structure of the native virus without containing infectious genetic material. The mechanism of action involves stimulating the immune system to produce neutralizing antibodies and T-cell responses against the RSV F protein, which is critical for viral entry into host cells. By targeting the F protein, the vaccine aims to prevent respiratory syncytial virus infections, particularly in vulnerable populations such as infants and the elderly. The eVLP technology is designed to enhance the immunogenicity of the antigen by presenting it in a highly organized, repetitive array that resembles a real virus particle.
- Other names
- RSV eVLPRSV F-VLPRespiratory syncytial virus fusion protein virus-like particle vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on respiratory syncytial virus fusion protein virus-like particle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on respiratory syncytial virus fusion protein virus-like particle.